Abstract 2042
Background
The Peritoneal Cancer Index (PCI) and completeness of cytoreduction are important prognostic factors in patients with peritoneal carcinomatosis from colorectal cancer, undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). The PCI is determined during laparotomy by an experienced surgeon before the decision is made to ‘do’ or ‘do not’ proceed with CRS-HIPEC. The aim of this study is to determine the accuracy of the clinical PCI score (cPCI), by comparing the cPCI with the pathological PCI (pPCI) score.
Methods
All consecutive patients who underwent CRS-HIPEC for peritoneal carcinomatosis from colorectal origin between February 2015 and June 2018 where identified. Relevant patient- and tumor related characteristics were collected.
Results
In total 119 patients were included in this study; 60 males (50.4%). Median age was 64 years [IQR 55-71]. The pPCI was lower than the cPCI score in 80 patients (67.2%), the score was equal in 38 patients (31.9%), and in 1 patient (0.8%) the pPCI was higher than the cPCI. The median total cPCI 11 (IQR 6-16) was significantly higher than the median pPCI, (pPCI=8, IQR 3-13, p < 0.001). In 21 patients (17.6%) the cPCI was overestimated ≥5 points. When patients were divided in different PCI categories, 0-5, 6-10, 11-15, ≥16 respectively, 39 patients (32.8%) moved to a lower pPCI category with corresponding better median survival rates.
Conclusions
Clinical determination of the PCI often results in overestimation of the score. Far-reaching consequences are tied to the macroscopic evaluation of the cPCI by the surgeon, but this evaluation is not very reliable. Further research is warranted to determine whether the pPCI is a better scoring method/more precise prognostic factor for oncological outcomes after CRS-HIPEC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5295 - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster Display session 2
Resources:
Abstract
5887 - Factors of importance in procuring tumoroids from colorectal liver metastasis biopsies for precision medicine.
Presenter: Lars Henrik Jensen
Session: Poster Display session 2
Resources:
Abstract
2196 - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity
Presenter: Marie-Christine Etienne-Grimaldi
Session: Poster Display session 2
Resources:
Abstract
2859 - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO.
Presenter: Daniele Rossini
Session: Poster Display session 2
Resources:
Abstract
3888 - Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
Presenter: Takeshi Nagasaka
Session: Poster Display session 2
Resources:
Abstract
1065 - Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: retrospective analysis of the panitumumab (Pmab) PRIME study
Presenter: Andrea Sartore-Bianchi
Session: Poster Display session 2
Resources:
Abstract
1702 - Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)
Presenter: Hiroyuki Yokoyama
Session: Poster Display session 2
Resources:
Abstract
5104 - A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)
Presenter: Samantha Di Donato
Session: Poster Display session 2
Resources:
Abstract
5285 - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first line treatment in metastatic colorectal cancer
Presenter: Giulia Martini
Session: Poster Display session 2
Resources:
Abstract
1790 - Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG
Presenter: Stephan Sahm
Session: Poster Display session 2
Resources:
Abstract